FDA Bundling Policy Should Require Full User Fee Payment – MDMA
This article was originally published in The Gray Sheet
Executive Summary
An FDA policy allowing less than full user fee payments for bundled premarket submissions would create a "disadvantage" for small manufacturers, the Medical Device Manufacturers Association states
You may also be interested in...
MDUFMA Guidance Clarifies Appropriate Bundling Use For Reprocessed SUDs
A Class II special surgical implant device used to implant a Class III device may be bundled in the same premarket approval application, according to an FDA bundling guidance
MDUFMA Guidance Clarifies Appropriate Bundling Use For Reprocessed SUDs
A Class II special surgical implant device used to implant a Class III device may be bundled in the same premarket approval application, according to an FDA bundling guidance
User Fees Hiked In FY ’04: Fewer Submissions, Bundling Cited As Factors
PMA submission trends over the next 12 months will help determine whether device user fees in fiscal 2005 continue to rise at the FY 2004 rate